<strong><em>Objective</em></strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">:<...<strong><em>Objective</em></strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">:</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> To evaluate the benefit of dual trigger (hCG + GnRH agonist) in patients underwent controlled ovarian stimulation for IVF in an antagonist protocol. </span><b><i><span style="font-family:Verdana;">Methods</span></i></b><span style="font-family:Verdana;">:</span><span style="font-family:Verdana;"> A retrospective case control study was performed (January 2017 to March 2019) in a single IVF center. The dual trigger group (n = 17), ovulation trigger was achieved with both hCG and GnRH agonist while in the single trigger group (n = 34), it was achieved by hCG alone. The first endpoint was the number of mature oocytes retrieved;the secondary endpoints were total number of oocytes retrieved, the number of cleaved embryos obtained (day 3) and blastocysts (day 5/day 6), the number of embryos transferred, the ongoing-pregnancy/miscarriage rate. </span><b><i><span style="font-family:Verdana;">Results</span></i></b><span style="font-family:Verdana;">:</span><span style="font-family:Verdana;"> The dual vs. the single group showed the followings. The number of retrieved oocytes of 7.1 vs. 6.4 (p = 0.68);mature oocytes of 4.6 vs. 4.1 (p = 0.62), day-3-embryos of 2.9 vs. 2.0 (p = 0.2), day-5/6-embryos of 0.3 vs. 0.03 (p = 0.13), transferred embryos of 2.1 vs. 1.8 (p = 0.48);ongoing pregnancy of 1 vs. 9 (p = 0.14);miscarriage of 0 vs. 2 (p = 1). </span><b><i><span style="font-family:Verdana;">Conclusion</span></i></b><span style="font-family:Verdana;">:</span><span style="font-family:Verdana;"> A dual trigger showed no additional clinical benefits. Future large studies are needed to demonstrate a real clinical advantage.</span></span></span></span>展开更多
文摘<strong><em>Objective</em></strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">:</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> To evaluate the benefit of dual trigger (hCG + GnRH agonist) in patients underwent controlled ovarian stimulation for IVF in an antagonist protocol. </span><b><i><span style="font-family:Verdana;">Methods</span></i></b><span style="font-family:Verdana;">:</span><span style="font-family:Verdana;"> A retrospective case control study was performed (January 2017 to March 2019) in a single IVF center. The dual trigger group (n = 17), ovulation trigger was achieved with both hCG and GnRH agonist while in the single trigger group (n = 34), it was achieved by hCG alone. The first endpoint was the number of mature oocytes retrieved;the secondary endpoints were total number of oocytes retrieved, the number of cleaved embryos obtained (day 3) and blastocysts (day 5/day 6), the number of embryos transferred, the ongoing-pregnancy/miscarriage rate. </span><b><i><span style="font-family:Verdana;">Results</span></i></b><span style="font-family:Verdana;">:</span><span style="font-family:Verdana;"> The dual vs. the single group showed the followings. The number of retrieved oocytes of 7.1 vs. 6.4 (p = 0.68);mature oocytes of 4.6 vs. 4.1 (p = 0.62), day-3-embryos of 2.9 vs. 2.0 (p = 0.2), day-5/6-embryos of 0.3 vs. 0.03 (p = 0.13), transferred embryos of 2.1 vs. 1.8 (p = 0.48);ongoing pregnancy of 1 vs. 9 (p = 0.14);miscarriage of 0 vs. 2 (p = 1). </span><b><i><span style="font-family:Verdana;">Conclusion</span></i></b><span style="font-family:Verdana;">:</span><span style="font-family:Verdana;"> A dual trigger showed no additional clinical benefits. Future large studies are needed to demonstrate a real clinical advantage.</span></span></span></span>
